117 related articles for article (PubMed ID: 38235574)
1. Myricetin, a natural inhibitor of CD147, increases sensitivity of cisplatin in ovarian cancer.
Chen L; Fan T; Wang M; Zhu CY; Feng WY; Li Y; Yang H
Expert Opin Ther Targets; 2024; 28(1-2):83-95. PubMed ID: 38235574
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis B X-interacting protein promotes cisplatin resistance and regulates CD147 via Sp1 in ovarian cancer.
Zou W; Ma X; Yang H; Hua W; Chen B; Cai G
Exp Biol Med (Maywood); 2017 Mar; 242(5):497-504. PubMed ID: 28056551
[TBL] [Abstract][Full Text] [Related]
3. Myricetin inhibits proliferation of cisplatin-resistant cancer cells through a p53-dependent apoptotic pathway.
Huang H; Chen AY; Ye X; Li B; Rojanasakul Y; Rankin GO; Chen YC
Int J Oncol; 2015 Oct; 47(4):1494-502. PubMed ID: 26315556
[TBL] [Abstract][Full Text] [Related]
4. RNAi-mediated silencing of CD147 inhibits tumor cell proliferation, invasion and increases chemosensitivity to cisplatin in SGC7901 cells in vitro.
Wang B; Xu YF; He BS; Pan YQ; Zhang LR; Zhu C; Qu LL; Wang SK
J Exp Clin Cancer Res; 2010 Jun; 29(1):61. PubMed ID: 20525232
[TBL] [Abstract][Full Text] [Related]
5. HIF-2α-dependent TGFBI promotes ovarian cancer chemoresistance by activating PI3K/Akt pathway to inhibit apoptosis and facilitate DNA repair process.
Ma S; Wang J; Cui Z; Yang X; Cui X; Li X; Zhao L
Sci Rep; 2024 Feb; 14(1):3870. PubMed ID: 38365849
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo prostate cancer metastasis and chemoresistance can be modulated by expression of either CD44 or CD147.
Hao J; Madigan MC; Khatri A; Power CA; Hung TT; Beretov J; Chang L; Xiao W; Cozzi PJ; Graham PH; Kearsley JH; Li Y
PLoS One; 2012; 7(8):e40716. PubMed ID: 22870202
[TBL] [Abstract][Full Text] [Related]
7. Novel Aurora A Kinase Inhibitor Fangchinoline Enhances Cisplatin-DNA Adducts and Cisplatin Therapeutic Efficacy in OVCAR-3 Ovarian Cancer Cells-Derived Xenograft Model.
Winardi D; Chu PY; Chen GY; Wang K; Hsu WY; Hsieh CL; Chen YH; Wu YC; Yang JC
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163790
[TBL] [Abstract][Full Text] [Related]
8. MiR-149-3p promotes the cisplatin resistance and EMT in ovarian cancer through downregulating TIMP2 and CDKN1A.
Wang J; Liu L
J Ovarian Res; 2021 Nov; 14(1):165. PubMed ID: 34798882
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effects of heparin-polyethyleneimine nanogels delivering claudin-3-targeted short hairpin RNA combined with low-dose cisplatin on ovarian cancer.
Liu L; Gou M; Yi T; Bai Y; Wei Y; Zhao X
Oncol Rep; 2014 Apr; 31(4):1623-8. PubMed ID: 24482188
[TBL] [Abstract][Full Text] [Related]
10. The Natural Compound Myricetin Effectively Represses the Malignant Progression of Prostate Cancer by Inhibiting PIM1 and Disrupting the PIM1/CXCR4 Interaction.
Ye C; Zhang C; Huang H; Yang B; Xiao G; Kong D; Tian Q; Song Q; Song Y; Tan H; Wang Y; Zhou T; Zi X; Sun Y
Cell Physiol Biochem; 2018; 48(3):1230-1244. PubMed ID: 30045021
[TBL] [Abstract][Full Text] [Related]
11. Bridge linkage role played by CD98hc of anti-tumor drug resistance and cancer metastasis on cisplatin-resistant ovarian cancer cells.
Yang H; Zou W; Li Y; Chen B; Xin X
Cancer Biol Ther; 2007 Jun; 6(6):942-7. PubMed ID: 17611393
[TBL] [Abstract][Full Text] [Related]
12. Label-free-based quantitative proteomic analysis of the inhibition of cisplatin-resistant ovarian cancer cell proliferation by cucurbitacin B.
Yin S; Mai Z; Liu C; Xu L; Xia C
Phytomedicine; 2023 Mar; 111():154669. PubMed ID: 36681055
[TBL] [Abstract][Full Text] [Related]
13. Novel role of lncRNA CHRF in cisplatin resistance of ovarian cancer is mediated by miR-10b induced EMT and STAT3 signaling.
Tan WX; Sun G; Shangguan MY; Gui Z; Bao Y; Li YF; Jia ZH
Sci Rep; 2020 Sep; 10(1):14768. PubMed ID: 32901049
[TBL] [Abstract][Full Text] [Related]
14. ARL6IP5 reduces cisplatin-resistance by suppressing DNA repair and promoting apoptosis pathways in ovarian carcinoma.
Kim JY; Bahar E; Lee JY; Chang S; Kim SH; Park EY; Do SI; Yoon H; Kim HS
Cell Death Dis; 2022 Mar; 13(3):239. PubMed ID: 35293383
[TBL] [Abstract][Full Text] [Related]
15. Enhanced antitumor effects of follicle-stimulating hormone receptor-mediated hexokinase-2 depletion on ovarian cancer mediated by a shift in glucose metabolism.
Zhang M; Liu Q; Zhang M; Cao C; Liu X; Zhang M; Li G; Xu C; Zhang X
J Nanobiotechnology; 2020 Nov; 18(1):161. PubMed ID: 33160373
[TBL] [Abstract][Full Text] [Related]
16. Myricetin suppresses TGF-β-induced epithelial-to-mesenchymal transition in ovarian cancer.
Yang HW; Lan Y; Li A; Wu H; Song ZW; Wan AL; Wang Y; Li SB; Ji S; Wang ZC; Wu XY; Lan T
Front Pharmacol; 2023; 14():1288883. PubMed ID: 38026996
[No Abstract] [Full Text] [Related]
17. shRNA-mediated AMBRA1 knockdown reduces the cisplatin-induced autophagy and sensitizes ovarian cancer cells to cisplatin.
Li X; Zhang L; Yu L; Wei W; Lin X; Hou X; Tian Y
J Toxicol Sci; 2016 Feb; 41(1):45-53. PubMed ID: 26763392
[TBL] [Abstract][Full Text] [Related]
18. Downregulated expression levels of USP46 promote the resistance of ovarian cancer to cisplatin and are regulated by PUM2.
Xu L; Zhang B; Li W
Mol Med Rep; 2021 Apr; 23(4):. PubMed ID: 33576437
[TBL] [Abstract][Full Text] [Related]
19. Ghrelin enhances cisplatin sensitivity in HO-8910 PM human ovarian cancer cells.
Leng Y; Zhao C; Yan G; Xu S; Yang Y; Gong T; Li X; Li C
J Ovarian Res; 2021 Nov; 14(1):162. PubMed ID: 34789301
[TBL] [Abstract][Full Text] [Related]
20. Low concentration of quercetin antagonizes the cytotoxic effects of anti-neoplastic drugs in ovarian cancer.
Li N; Sun C; Zhou B; Xing H; Ma D; Chen G; Weng D
PLoS One; 2014; 9(7):e100314. PubMed ID: 24999622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
